Overall, these data suggest that serum miR-301a, in combination with examination of TGF-β and IL-6, might be a fibrosis marker for fibrosis in patients with chronic pancreatitis and early pancreatic cancer. This evidence concerns the gene TGFB1 and chronic pancreatitis.